Trial Profile

A Phase I Clinical Trial of Human CD19/BCMA Bispecific CAR-T Cell Therapy for Subjects With Relapsed and Refractory POMES Syndrome.

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti CD19 anti BCMA bispecific chimeric antigen receptor T cell therapy Hrain Biotechnology (Primary) ; Cyclophosphamide; Fludarabine
Indications POEMS syndrome
Focus Adverse reactions
Sponsors Hrain Biotechnology

Most Recent Events

05 Aug 2021 Planned End Date changed from 1 Feb 2022 to 30 May 2022.
05 Aug 2021 Status changed from recruiting to active, no longer recruiting.
02 Apr 2019 Planned initiation date changed from 1 Mar 2019 to 1 May 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com